Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 20:36:45时区推断·⟳ 抓取 20:45:13·⚡ 决策 07-27 20:49:43 +4m30s·91.9 天前
Entera Bio宣布2.75亿美元私募融资以推进EB613三期研究
2.75亿美元融资相对公司此前约2040万美元现金非常大，若顺利交割可把运营资金延长至2030年并支持EB613三期注册研究。
📄 原文Investing.com↗ 原文
Entera Bio raises $275 million in private placement for phase 3
Oil prices tumble over 8% amid halt to fighting between U.S., Iran TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) announced t…
不做 Entera Bio（ENTX.US）
不做：融资可延长runway但同时大比例摊薄，且EB613三期方案早已披露、临床读出在2028年，当前事件方向混合且盘前已偏负反应，无法形成同向正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 报道Entera Bio达成约2.75亿美元私募融资协议，资金用于EB613三期、EB612一期及营运资金，属于融资而非临床结果。市场反应:报道页显示ENTX盘前/相关行情为-3.76%，说明市场未把该融资单纯解读为追多利好。
- 公司此前已披露FDA同意EB613约750人、12个月总髋BMD为主要终点的三期方案，三期计划2026年末启动、2028年下半年读出。
关键理由
- 2.75亿美元融资相对公司此前约2040万美元现金非常大，若顺利交割可把运营资金延长至2030年并支持EB613三期注册研究。
- 但公司将发行约1.35亿股普通股及预融资权证，融资价格2.04美元，短期核心变量是显著摊薄与定增价格锚定，而非临床或商业化新增成功。
- EB613仍需2026年末启动三期、2028年下半年读出，当前融资本身不带来近期收入或监管批准，难形成清晰同向交易。
主要风险
- 融资需常规交割条件，且大规模新增股份可能压制短线股价反应。
- EB613商业化仍处三期前阶段，新增资金解决 runway 但不降低临床失败风险。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-06-22 · 影响 weakens
EB613三期计划和FDA反馈已在6月披露，本次新增信息是融资本身，利好被大规模摊薄和发行价锚定抵消。
检索:Entera Bio EB613 Phase 3 timeline cash runway dilution private placement 2026 原文 ↗
原文全文
展开原文 · 2,121 字
Oil prices tumble over 8% amid halt to fighting between U.S., Iran
TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) announced today that it has entered into a securities purchase agreement for a private placement expected to generate gross proceeds of approximately $275 million before fees and expenses.
The financing is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital and Catalio Capital Management.
Under the agreement, the company will issue 122,961,215 ordinary shares and pre-funded warrants to purchase up to 11,842,695 ordinary shares. The purchase price per ordinary share is $2.04, according to the press release statement. The pre-funded warrants have an exercise price of NIS 0.0000769 per ordinary share, are immediately exercisable and have no expiration date.
The private placement is expected to close on or about Monday, subject to customary closing conditions. Upon closing, BVF will receive the right to designate two directors to the company’s board of directors, subject to applicable requirements.
Entera stated the net proceeds, combined with existing cash and cash equivalents, are expected to fund operations into 2030. The company plans to use the funds to support Phase 3 registrational studies for EB613, an oral PTH(1-34) peptide tablet in development for osteoporosis treatment, advance EB612 into Phase 1 development in collaboration with OPKO Health for hypoparathyroidism treatment, and for working capital and general corporate purposes.
Leerink Partners is acting as lead placement agent, with Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital and Canaccord Genuity serving as co-placement agents.
The securities are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) announced today that it has entered into a securities purchase agreement for a private placement expected to generate gross proceeds of approximately $275 million before fees and expenses.
The financing is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital and Catalio Capital Management.
Under the agreement, the company will issue 122,961,215 ordinary shares and pre-funded warrants to purchase up to 11,842,695 ordinary shares. The purchase price per ordinary share is $2.04, according to the press release statement. The pre-funded warrants have an exercise price of NIS 0.0000769 per ordinary share, are immediately exercisable and have no expiration date.
The private placement is expected to close on or about Monday, subject to customary closing conditions. Upon closing, BVF will receive the right to designate two directors to the company’s board of directors, subject to applicable requirements.
Entera stated the net proceeds, combined with existing cash and cash equivalents, are expected to fund operations into 2030. The company plans to use the funds to support Phase 3 registrational studies for EB613, an oral PTH(1-34) peptide tablet in development for osteoporosis treatment, advance EB612 into Phase 1 development in collaboration with OPKO Health for hypoparathyroidism treatment, and for working capital and general corporate purposes.
Leerink Partners is acting as lead placement agent, with Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital and Canaccord Genuity serving as co-placement agents.
The securities are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。